The landscape of breast cancer treatment is undergoing a seismic shift. As systemic therapies become more refined and less toxic—particularly with the advent of CDK4/6 inhibitors—patients are living significantly longer with metastatic disease. This extended survival brings new clinical challenges, most notably the emergence of resistant cancer clones. At the forefront of this evolution is Dr. Imogen Locke of The Royal Marsden NHS Foundation Trust, who is currently championing the precise application of stereotactic ablative radiotherapy (SABR) to manage oligometastatic and oligoprogressive disease.
In a recent, wide-ranging interview, Dr. Locke discussed the clinical dilemmas facing modern oncologists and the transformative potential of personalized, biology-driven radiotherapy.
Main Facts: Redefining Metastatic Management
The traditional approach to metastatic breast cancer has historically been systemic, focusing on the whole body rather than individual lesions. However, the paradigm is changing. Dr. Locke highlights a distinction between two critical clinical scenarios:
- Oligometastatic Disease: Defined as a limited state of spread—typically five or fewer lesions. These can be synchronous (present at initial diagnosis) or metachronous (developing after a period of disease control).
- Oligoprogressive Disease: A more complex state where a patient has widespread metastatic disease controlled by systemic therapy, but begins to show localized progression in a few isolated sites.
The primary objective for oncologists like Dr. Locke is to determine whether "metastasis-directed therapy"—specifically SABR—can ablate these resistant clones to extend patient survival or allow patients to remain on their current, low-toxicity systemic drug regimens for longer, thereby delaying the need for more aggressive and toxic treatments.
Chronology: From Prolonged Treatment to One-Week Standards
To understand the current state of radiotherapy, one must look at how rapidly the field has advanced over the last two decades.
- The Early 2000s: Standard adjuvant radiotherapy protocols typically required five to six weeks of daily hospital visits, a significant burden on patients’ quality of life and resources.
- The Transition Phase: Through the development of hypofractionation and improved imaging, the time commitment began to shrink. Research focused on demonstrating that shorter courses of high-dose radiation were just as effective as the traditional long-course treatments.
- The Current Standard: Today, approximately 70% of women in the UK undergoing adjuvant breast radiotherapy are treated in just one week (five fractions).
- The Future Outlook: Trials like the FAST-forward study are currently working to determine if this one-week standard can be applied universally, including for patients with complex needs, such as those requiring tumor bed boosts or treatment of internal mammary lymph nodes.
Supporting Data: Evidence, Trials, and Clinical Realities
The clinical application of SABR is not without its controversies. Dr. Locke notes that while the potential is high, the data must guide the practice.
The Role of Imaging and Biomarkers
A major challenge in treating oligoprogressive disease is "hidden" burden. As illustrated by Dr. Locke’s case study of a patient with triple-negative breast cancer (TNBC), imaging can sometimes be misleading. A patient might appear to have a single, treatable nodule on a PET scan, yet possess significant microscopic disease elsewhere.
"The challenge is defining that state better," says Dr. Locke. She points to the potential of circulating tumor DNA (ctDNA) as a future tool for patient selection. In the CURB trial, researchers found that in lung cancer patients, a drop in ctDNA correlated with the success of SABR. While this is not yet a routine clinical tool for breast cancer, it represents the next generation of precision oncology: matching the treatment to the biological reality of the patient’s disease.
Toxicity and Precision
One of the most significant advantages of SABR is its high degree of focus. Because the radiation dose "falls off" rapidly, it spares surrounding healthy tissue. Consequently, despite delivering high doses to target lesions, the treatment is remarkably well-tolerated, with toxicity rarely acting as a primary barrier to care.
Official Responses and Clinical Dilemmas
Dr. Locke’s perspective as a consultant at The Royal Marsden provides a unique window into the decision-making process at a world-leading cancer center. Her approach to the timing of radiotherapy is inherently cautious, particularly in the UK context:
- Commissioning Constraints: In England, SABR is currently commissioned primarily for metachronous oligometastatic disease. The logic is that a prolonged disease-free interval indicates a more indolent biology, making the patient a better candidate for ablative intervention.
- Systemic Integration: Before recommending SABR, clinicians generally prefer to see a patient established on systemic therapy for several months. This ensures that the patient is truly in an oligometastatic state and that their systemic treatment is effectively controlling the disease at large.
- The "Value" Paradigm: In oligoprogressive cases, the goal isn’t necessarily to cure the disease, but to obtain "more value" from the current, low-toxicity therapy. By "zapping" a resistant clone, the oncologist may keep the patient on a successful, non-toxic drug for an extra year or more.
Implications: The Future of Personalized Radiotherapy
The future of breast cancer radiotherapy is moving away from a "one-size-fits-all" model toward a deeply personalized, translational approach.
Expanding the Trial Portfolio
The UK is currently a hub for innovative breast cancer research. Dr. Locke points to several key trials that are poised to change clinical practice:
- The PARABLE Trial: Investigating the role of protons in adjuvant radiotherapy.
- The PRADA2 Trial: Assessing the impact of radiotherapy sequencing on outcomes for patients undergoing DIEP reconstruction.
- Auxiliary De-escalation: Research is ongoing to determine how much we can reduce treatment to the axilla without compromising survival, further limiting side effects.
The Shift to Biological Personalization
As the interview concludes, Dr. Locke emphasizes that the next great leap in oncology will be the marriage of radiotherapy with the underlying biology of the tumor and the patient.
"We’ve got a lot of translational studies going on," Locke notes. "Being able to personalize the radiotherapy to the underlying biology of the cancer and of the person will be the next focus."
The integration of routine ctDNA monitoring, the refinement of imaging modalities, and the continued results from the UK’s robust clinical trial portfolio suggest that the next decade will be defined by "precision radiotherapy." For the patient, this means shorter, more effective, and less toxic treatment pathways that are increasingly tailored to the specific behavior of their cancer.
A New Standard of Care
For clinicians, the takeaway is clear: the era of treating every breast cancer case with the same standardized, long-term protocol is ending. In its place is a more nuanced, agile, and evidence-based approach. By carefully selecting patients for SABR, monitoring disease progression through sophisticated molecular tools, and participating in the latest clinical trials, oncologists are successfully transforming what was once a terminal diagnosis into a manageable, long-term condition.
As Dr. Locke observes, we are not just on the cusp of answering the most pressing questions in radiotherapy—we are actively redefining the boundaries of what is possible for breast cancer patients worldwide.
Disclaimer: The opinions expressed in this article are those of the featured expert and do not necessarily reflect the views of the publication or its affiliates. The information provided is for educational purposes and should not be considered medical advice.
About the Author
